Formulated for type 2 diabetes mellitus to manage blood glucose and support weight reduction.
Mechanism of Action
Semaglutide acts as a glucagon-like peptide-1 receptor agonist. It enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion, and delays gastric emptying, which leads to improved glycemic control and decreased appetite.
Route of Administration
Oral
Onset Time
1–2 weeks
Duration
1 week
Contraindications
Medullary thyroid carcinoma history, Multiple endocrine neoplasia syndrome type 2, Hypersensitivity to semaglutide
Severe Adverse Events
Pancreatitis, Diabetic retinopathy complications, Medullary thyroid cancer — requires immediate medical attention
Information related to Semaglutide is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
